Protective role of oryeongsan against renal inflammation and glomerulosclerosis in db/db mice

American Journal of Chinese Medicine

Volumn 42, Issue 6, 2014, Pages 1431-1452

  Yoon, Jung Joo ^a,b   Lee, Yun Jung ^a,b   Kang, Dae Gill ^a,b   Lee, Ho Sub ^a,b  

^a Wonkwang University   (South Korea)

^b Wonkwang University   (South Korea)

Author keywords

Diabetic Nephropathy; Glomerulosclerosis; Inflammation; Oryeongsan; Smads; TGF 1

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; HERBACEOUS AGENT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; ORYEONGSAN; PROTECTIVE AGENT; SMAD2 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; INTERCELLULAR ADHESION MOLECULE-1; PLANT EXTRACTS; SMAD PROTEINS; WULINGSAN;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DB/DB MOUSE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INVESTIGATIVE PROCEDURES; KIDNEY FIBROSIS; MALE; MOUSE; NEPHRITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ANIMALS; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG EFFECTS; METABOLISM; MICE, INBRED STRAINS; PHYTOTHERAPY; SIGNAL TRANSDUCTION;

ANIMALS; BODY WEIGHT; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; MALE; MICE, INBRED STRAINS; PHYTOTHERAPY; PLANT EXTRACTS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84929310448     PISSN: 0192415X     EISSN: 17936853     Source Type: Journal    
DOI: 10.1142/S0192415X14500906     Document Type: Article

References (48)

1. Adams, L.A. and P. Angulo. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin. Liver. Dis. 11: 25-35, 2004.
2. Ahn, Y.M., K.W. Cho, D.G. Kang and H.S. Lee. Orye ongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin-angiotensin-aldosterone system in rats. J. Ethnopharmacol. 141: 780-785, 2012.
3. Border W.A. N.A. Noble Transforming growth factor-? in tissue fibrosis. New. Engl. J. Med. 331 1286-1292 1994.
4. Chao, C.Y., M.C. Mong, K.C. Chan and M.C. Yin. Anti-glycative and anti-inflammatory effects of caffeic acid and ellagic acid in kidney of diabetic mice. Mol. Nutr. Food. Res. 54: 388-395, 2010.
5. Chen, H., O. Charlat, L.A. Tartaglia, E.A. Woolf, X. Weng, S.J. Ellis, N.D. Lakey, J. Culpepper, K.J. Moore, R.E. Breitbart, G.M. Duyk, R.I. Tepper and J.P. Morgenstern. Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495, 1996.
6. Chen, Y.C., C.Y. Ho, L.D. Chen, S.F. Hsu and W.C. Chen. Wu-Ling-San Formula inhibits the crystallization of calcium oxalate in vitro. Am. J. Chin. Med. 35: 533-541, 2007.
7. Chiarelli, F., A. Verrotti, A. Mohn and G. Morgese. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: Therapeutic implications. Ann. Med. 29: 439-445, 1997.
8. Cohen, M.P., G.T. Lautenslager and C.W. Shearman. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care 24: 914-918, 2001.
9. De Zeeuw, D., G. Remuzzi, H.H. Parving, W.F. Keane, Z. Zhang, S. Shahinfar, S. Snapinn, M.E. Cooper, W.E. Mitch and B.M. Brenner. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 65: 2309-2320, 2004.
10. Det van, N.F., J. Van den Born, J.T. Tamsma, N. Verhagen, J.H. Berden, J.A. Bruijn, M.R. Daha and F.J. Van Der Woude. Effects of high glucose on the production of heparan sulfate proteoglycan by mesangial and epithelial cells. Kidney Int. 49: 1079-1089, 1996.
11. Dong, F.Q., H. Li, W.M. Cai, J. Tao, Q. Li, Y. Ruan, F.P. Zheng and Z. Zhang. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin. Med. J. 117: 1040-1044, 2004.
12. Eddy, A.A. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 7: 2495-2508, 1996.
13. Group UPDSU. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes S tudy (UKPDS) Group. Lancet 352: 837-853, 1998.
14. Hattori, T., N. Fujitsuka, A. Kurogi and S. Shindo. Sairei-to may inhibit the synthesis of endothelin-1 in nephritic glomeruli. Nippon. Jinzo. Gakkai. Shi. 39: 121-128, 1997.
15. Henry, R.R. Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes. Clin. Ther. 25(Suppl B): B47-B63, 2003.
16. Huang, S.K., E.S. White, S.H. Wettlaufer, H. Grifka, C.M. Hogaboam, V.J. Thannickal, J.C. Horowitz and M. Peters-Golden. Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways. FASEB J. 23: 4317-4326, 2009.
17. Hwang, S.M., J.S. Kim, Y.J. Lee, J.J. Yoon, S.M. Lee, D.G. Kang and H.S. Lee. Anti-diabetic atherosclerosis effect of Prunella vulgaris in db/db mice with type 2 diabetes. Am. J. Chin. Med. 40: 937-951, 2012.
18. Ibrahim, H.M. and T.H. Hostetter. Diabetic nephropathy. J. Am. Soc. Nephrol. 8: 487-493, 1997.
19. Ito, Y., R. Goldschmeding, R. Bende, N. Claessen, M. Chand, L. Kleij, T. Rabelink, J. Weening and J. Aten. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nep hrol. 12: 472-484, 2001.
20. Janssens, S. and H.R. Lijnen. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cadiovas. Res. 69: 585-594, 2006.
21. Jiang, W., Y. Zhang, H. Wu, X. Zhang, H. Gan, J. Sun, Q. Chen, M. Guo and Z. Zhang. Role of cross-talk between the Smad-2 and MAPK pathways in TGF beta1-induced collagen IV expression i n mesangial cells. Int. J. Mol. Med. 26: 571-576, 2010.
22. Josephine, M.F., T.C. Melinda and E.C. Mark. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57: 1446-1454, 2008.
23. Katz, A., S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann, G. Sullivan and M.J. Quon. Quantitative insulin sensitivity check index: A simple, accurate method for assessing ins ulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85: 2402-2410, 2000.
24. Kobayashi K. T.M. Forte S. Taniguchi B.Y. Ishida K. Oka L. Chan. The db/db mouse, a model for diabetic dyslipidemia: Molecular characterization and effect of Western diet feeding. Metabolism 49 22-31 2000.
25. Koya, D., M. Haneda, H. Nakagawa, K. Isshiki, H. Sato, S. Maeda, T. Sugimoto, H. Yasuda, A. Kashiwagi, D.K. Ways, G.L. King and R. Kikkawa. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC-? inhibitor in diabetic db/db mic e, a rodent model for type 2 diabetes. FASEB J. 14: 439-447, 2000.
26. Kunwar, P.S., M. Starz-Gaiano, R.J. Bainton, U. Heberlein and R. Lehman. Tre1, a G protein-coupled receptor, directs transepithelial migration of Drosophila germ cells. PLoS Biol. 1: E80, 2003.
27. Lee, A.S., Y.J. Lee, S.M. Lee, J.J. Yoon, J.S. Kim, D.G. Kang and H.S. Lee. An aqueous extract of Portulaca oleracea ameliorates diabetic nephropathy through suppression of renal fibrosis and inflammation in diabetic db/db mice. Am. J. Chin. Med. 40: 495-510, 2012.
28. Li, J., S.S. Lim, J.Y. Lee, J.K. Kim, S.W. Kang, J.L. Kim and Y.H. Kang. Purple corn anthocyanins dampened high-glucose-induced mesangial fibrosis and inflammation: Possible renoprotective role in diabetic nephropathy. J. Nu tr. Biochem. 23: 320-331, 2012.
29. Liu, Q.L., S. Sato, T. Kishikawa, H. Matsuzaki and N. Yamanaka. Effectiveness of a traditional Chinese medicine, Wulingsan, in suppressing the development of nephrocalcinosis induced by a high phosphorus diet in young rats. Med. Electron. Microsc. 34: 103-114, 2001.
30. Makino, H., M. Mukoyama, A. Sugawara, K. Mori, T. Suganami, K. Yahata, Y. Fujinaga, H. Yokoi, I. Tanaka and K. Nakao. Roles of connective tissue growth factor and prostanoids in early streptozotocin-induced diabetic rat kidney: The effect of aspirin treatment. Clin. Exp. Nephrol. 7: 33-40, 2003.
31. Matsubara, T., H. Abe, H. Arai, K. Nagai, A. Mima, H. Kanamori, E. Sumi, T. Takahashi, M. Matsuura, N. Iehara, A. Fukatsu, T. Kita and T. Doi. Expression of Smad1 is directly assoc iated with mesangial matrix expansion in rat diabetic nephropathy. Lab. Invest. 86: 357-368. 2006.
32. Mora, C. and J.F. Navarro. The role of inflammation as a pathogenic factor in the development of renal disease in diabetes. Curr. Diab. Rep. 5: 399-401, 2005.
33. Okada, S., K. Shikata, M. Matsuda, D. Ogawa, H. Usui, Y. Kido, R. Nagase, J. Wada, Y. Shikata and H. Makino. Intercellul ar adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003.
34. Parsons, C.J., M. Takashima and R.A. Rippe. Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22: S79-S84, 2007.
35. Pfeiffer, A., K. Middelberg-Bisping, C. Drewes and H. Schatz. Elevated plasma levels of transforming growth factor-?1 in NIDDM. Diabetes Care 19: 1113-1117, 1996.
36. Phyllis, A. and S. Manikkam. Transforming growth factor beta and progression of renal disease. Kidney Int. 64: S99-S104, 2003.
37. Sharma, K., Y. Jin, J. Guo and F.N. Ziyadeh. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZinduced diabetic mice. Diabetes 45: 522-530, 1996.
38. Sharma, K. and F.N. Ziyadeh. Hyperglycemia and diabetic kidney disease: The case for transforming growth factor-? as a key mediator. Diabetes 44: 1139-1146, 1995.
39. Sugimoto, H., G. Grahovac, Z. Michae and R. Kalluri. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 56: 1825-1833, 2007.
40. Sung, S.H., F.N. Ziyadeh, A. Wang, P.E. Pyagay, Y.S. Kanwar and S. Chen. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17: 3093-3104, 2006.
41. Thomson, S.V., S.V. McLennan, P.D. Kirwan, S.J. Heffernan, A. Hennessy, D.K. Yue and S.M. Twigg. Renal connective tissue growth factor correlates with glomerular basement membrane thick ness and prospective albuminuria in a non-human primate model of diabetes: Possible predictive marker for incipient diabetic nephropathy. J. Diabetes Complicat. 22: 284-294, 2008.
42. Twigg, S.M., A.H. Joly, M.M. Chen, J. Tsubaki, H.S. Kim, V. Hwa, Y. Oh and R.G. Rosenfeld. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in hum an dermal fibroblasts. Endocrinology 143: 1260-1269, 2002.
43. Twigg, S.M. and M.E. Cooper. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 47: 965-968, 2004.
44. Viberti, G. and N.M. Wheeldon. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002.
45. Wallace, T.M., J.C. Levy and D.R. Matthews. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
46. Xavier S. E. Piek M. Fujii D. Javelaud A. Mauviel K.C. Flanders Amelioration of radiationinduced fibrosis: Inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 279 15167-15176 2004.
47. Yoon, J.J., Y.J. Lee, S.M. Lee, S.N. Jin, D.G. Kang and H.S. Lee. Poria cocos inhibits high glucoseinduced proliferation of rat mesangial cells. Am. J. Chin. Med. 41: 71-83, 2013.
48. Zhang, Z., X. Luo, S. Ding, J. Chen, T. Chen, X. Chen, H. Zha, L. Yao, X. He and H. Peng. MicroRNA-451 regulates p38 MAPK signaling by targeting of Ywhaz and suppresses the mesangial hypertrophy in early diabetic nephropathy. FEBS Lett. 586: 20-23, 2012.